Ionis Pharmaceuticals (IONS) received an approval recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, for Tryngolza's indication extension to include the treatment of adult patients with severe hypertriglyceridemia, the company said Friday.
The CHMP's positive recommendation was based on the results of two phase 3 studies that met their primary endpoint of demonstrating a significant reduction in fasting triglyceride levels, Ionis said.
Ionis also noted that the recommendation came earlier than expected, with the European Commission's final decision expected in Q4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments